Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix estimates Q3 TONMYA net revenue of $14.0 million to $15.0 million

Neutral Impact 3 of 5 earnings Written later

Tonix Pharmaceuticals disclosed preliminary, unaudited results for the quarter ended September 30, 2026, estimating TONMYA net revenue of $14.0 million to $15.0 million and cash and cash equivalents of approximately $162.8 million. The company warned that financial closing procedures are incomplete and final results could differ materially, so shareholders should treat the figures as provisional.

Key points

  • Estimated three-month TONMYA net revenue: $14.0 million to $15.0 million
  • Estimated cash and cash equivalents as of September 30, 2026: approximately $162.8 million
  • Figures are preliminary and subject to revision; the company has not completed financial closing procedures
  • Filing made under Item 2.02 with Item 8.01 incorporating the same information

The filing

CompanyTonix Pharmaceuticals Holding Corp. (TNXP)
Form8-K, current report
Filed with the SECOct 15, 2026, 7:00 AM ET
Accession number0001493152-26-047139

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.